免疫检查点阻滞剂抗程序性死亡分子1(PD-1)/PD-1配体(PD-L1)抗体类药物的研发是目前肿瘤治疗领域的研究热点.越来越多的临床试验证实抗PD-1/PD-L1抗体在各类肿瘤的治疗中具有良好的疗效和安全性.研究已证实该类药物在实体瘤中具有显著疗效,其在淋巴瘤治疗中的独特机制也逐渐被发现,文章就PD-1在B细胞淋巴瘤中的最新研究进展进行介绍.%The inhibitors of programmed death 1 (PD-1)/PD-1 ligand (PD-L1) become a highlight in tumor immunotherapy and provide a new direction for immune-targeted therapy for cancer. More and more studies have confirmed that PD-1/PD-L1 inhibitors could improve effects and be well-tolerated. Early clinical trials of PD-1 inhibitors have shown significant clinical efficacy in various solid tumours. The unique role of the PD-1 pathway in lymphoma has been found gradually. This article summarized the advancement of PD-1 in B-cell lymphoma therapy.
展开▼
